Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. It offers A+Pre, a device that prepares blood samples for testing; the AC-1000, a device that separates cancer cells from the rest of the blood; A+SCDrop, a device that isolates individual cells; and A+CellScan, a device that stains and automatically counts cancer cells. The company provides developed dye kits used to identify different types of cancer cells. It also offers FinTruth financial verification agent platform, an enterprise AI financial verification platform designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules, and to produce source-traceable and auditable results. The company was founded in 2014 and is based in Tsuen Wan, Hong Kong.…
Advanced Biomed (NASDAQ: ADVB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 12 employees.
The shares were at 1.650 USD on 20 November 2026, down 80.0% over 52 weeks. Its 52-week range is 1.580 USD to 24.23 USD: the price is 93.2% below the high and 4.4% above the low.
Its market capitalisation is 2.73M USD.
Advanced Biomed reports return on equity of 54.4%.
Its debt exceeds its cash by 692.68K USD, a debt-to-equity ratio of 8.78. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.